亚博全站手机网页登录 - 歡迎您!

微生物与传染病学

张绮

Contact Us:
Tel: 62797532
E-mail: zhangqi2013 at mail.tsinghua.edu.cn
WeChat public account:

张绮,现为清华大学亚博全站手机网页登录副研究员,2005年本科毕业于武汉大学,2013年博士毕业于德国马丁路德大学。同年加入清华大学亚博全站手机网页登录张林琦教授组进行博士后研究,2017年入职清华大学亚博全站手机网页登录,担任助理研究员。

主要的研究领域包括抗病毒中和抗体的分离与鉴定、抗体药物的研发、病毒与免疫系统的相互作用关系等。张绮于2016年分离得到我国第一株抗埃博拉中和抗体,在动物模型中展示了显著的保护效力。2020年成功筛选出新冠特异性中和抗体组合物BRII-196/BRII-198(安巴韦单抗/罗米司韦单抗),并积极参与推进临床试验。该抗体组合疗法于2021年12月8日被我国药监局批准上市,成为我国第一个抗新冠病毒特效药物。国家卫健委于2022年3月已将该药纳入《新型冠状病毒肺炎诊疗方案(试行第九版)》,用于抗新冠病毒治疗。近年来以第一/共第一作者在Nature, Immunity, Nature Communications等杂志发表文章数篇,发明专利数十项。

•Liang Q, Wang Y, Zhang S, Sun J, Sun W, Li J, Liu Y, Li M, Cheng L, Jiang Y, Wang R, Zhang R, Yang Z, Ren Y, Chen P, Gao P, Yan H, Zhang Z,Zhang Q, Shi X, Wang J, Liu W, Wang X, Ying B, Zhao J, Qi H, Zhang L. RBD trimer mRNA vaccine elicits broad and protective immune responses against SARS-CoV-2 variants. iScience. 2022 Apr 15;25(4):104043.

•Shan S, Luo S, Yang Z, Hong J, Su Y, Ding F, Fu L, Li C, Chen P, Ma J, Shi X,Zhang Q, Berger B, Zhang L, Peng J. Deep learning guided optimization of human antibody against SARS-CoV-2 variants with broad neutralization. Proc Natl Acad Sci U S A. 2022 Mar 15;119(11):e2122954119.

•Shan S, Mok CK, Zhang S, Lan J, Li J, Yang Z, Wang R, Cheng L, Fang M, Aw ZQ, Yu J,Zhang Q, Shi X, Zhang T, Zhang Z, Wang J, Wang X, Chu JJH, Zhang L. A Potent and Protective Human Neutralizing Antibody Against SARS-CoV-2 Variants. Front Immunol. 2021 Dec 13;12:766821.

•Niu M, Wong YC, Wang H, Li X, Chan CY,Zhang Q, Ling L, Cheng L, Wang R, Du Y, Yim LY, Jin X, Zhang H, Zhang L, Chen Z. Tandem bispecific antibody prevents pathogenic SHIVSF162P3CN infection and disease progression. Cell Rep. 2021 Aug 24;36(8):109611.

•Wang R*,Zhang Q*, Ge J*, Ren W, Zhang R, Lan J, Ju B, Su B, Yu F, Chen P, Liao H, Feng Y, Li X, Shi X, Zhang Z, Zhang F, Ding Q, Zhang T*, Wang X*, Zhang L*. Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species. Immunity. 2021 Jul 13;54(7):1611-1621.e5. (co-first author, equally contributed)

Zhang Q*, Ju B*, Ge J*, Chan JF*, Cheng L*, Wang R*, Huang W*, Fang M, Chen P, Zhou B, Song S, Shan S, Yan B, Zhang S, Ge X, Yu J, Zhao J, Wang H, Liu L, Lv Q, Fu L, Shi X, Yuen KY, Liu L, Wang Y, Chen Z*, Zhang L*, Wang X*, Zhang Z*. Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2. Nat Commun. 2021 Jul 9;12(1):4210.

•Li M, Guo J, Lu S, Zhou R, Shi H, Shi X, Cheng L, Liang Q, Liu H, Wang P, Wang N, Wang Y, Fu L, Xing M, Wang R, Ju B, Liu L, Lau SY, Jia W, Tong X, Yuan L, Guo Y, Qi H,Zhang Q, Huang Z, Chen H, Zhang Z, Chen Z, Peng X, Zhou D, Zhang L. Single-Dose Immunization With a Chimpanzee Adenovirus-Based Vaccine Induces Sustained and Protective Immunity Against SARS-CoV-2 Infection. Front Immunol. 2021 Jun 28;12:697074.

•Yan R, Wang R, Ju B, Yu J, Zhang Y, Liu N, Wang J,Zhang Q, Chen P, Zhou B, Li Y, Shen Y, Zhang S, Tian L, Guo Y, Xia L, Zhong X, Cheng L, Ge X, Zhao J, Wang HW, Wang X, Zhang Z, Zhang L, Zhou Q. Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies. Cell Res. 2021 May;31(5):517-525.

•Zhou D, Chan JF, Zhou B, Zhou R, Li S, Shan S, Liu L, Zhang AJ, Chen SJ, Chan CC, Xu H, Poon VK, Yuan S, Li C, Chik KK, Chan CC, Cao J, Chan CY, Kwan KY, Du Z, Lau TT,Zhang Q, Zhou J, To KK, Zhang L, Ho DD, Yuen KY, Chen Z. Robust SARS-CoV-2 infection in nasal turbinates after treatment with systemic neutralizing antibodies. Cell Host Microbe. 2021 Apr 14;29(4):551-563.e5.

•Ge J*, Wang R*, Ju B*,Zhang Q*, Sun J, Chen P, Zhang S, Tian Y, Shan S, Cheng L, Zhou B, Song S, Zhao J, Wang H, Shi X, Ding Q, Liu L, Zhao J, Zhang Z, Wang X, Zhang L. Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry. Nat Commun. 2021 Jan 11;12(1):250. (co-first author, equally contributed)

•Li H, Zhao C, Zhang Y, Yuan F,Zhang Q, Shi X, Zhang L, Qin C, Zheng A. Establishment of replication-competent vesicular stomatitis virus-based recombinant viruses suitable for SARS-CoV-2 entry and neutralization assays. Emerg Microbes Infect. 2020 Dec;9(1):2269-2277.

•Li H, Zhao C, Zhang Y, Yuan F,Zhang Q, Shi X, Zhang L, Qin C, Zheng A. Establishment of replication-competent vesicular stomatitis virus-based recombinant viruses suitable for SARS-CoV-2 entry and neutralization assays. Emerg Microbes Infect. 2020 Dec;9(1):2269-2277.

•Li Q*, Wu J*, Nie J*, Zhang L*, Hao H, Liu S, Zhao C,Zhang Q, Liu H, Nie L, Qin H, Wang M, Lu Q, Li X, Sun Q, Liu J, Zhang L, Li X, Huang W, Wang Y. The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity. Cell. 2020 July. DOI: https://doi.org/10.1016/j.cell.2020.07.012

•Ju B*,Zhang Q*, Ge J*, Wang R, Sun J, Ge X, Yu J, Shan S, Zhou B, Song S, Tang X, Yu J, Lan J, Yuan J, Wang H, Zhao J, Zhang S, Wang Y, Shi X, Liu L, Zhao J, Wang X, Zhang Z& Zhang L. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. 2020 May. DOI: https://doi.org/10.1038/s41586-020-2380-z. (co-first author, equally contributed)

•Lan J*, Ge J*, Yu J*, Shan S*, Zhou H, Fan S,Zhang Q, Shi X, Wang Q, Zhang L& Wang X. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020 March.

•Wu X, Guo J, Niu M, An M, Liu L, Wang H, Jin X,Zhang Q, Lam KS, Wu T, Wang H, Wang Q, Du Y, Li J, Cheng L, Tang HY, Shang H, Zhang L, Zhou P, Chen Z. Tandem bispecific neutralizing antibody eliminates HIV-1 infection in humanized mice. J Clin Invest. 2018 Feb 20. pii: 96764. DOI: 10.1172/JCI96764.

•Yu L, Wang R, Gao F, Li M, Liu J, Wang J,Hong W, Zhao L, Wen Y, Yin C, Wang H,Zhang Q, Li Y, Zhou P, Zhang R, Liu Y, Tang X, Guan Y, Qin CF, Chen L, Shi X, Jin X, Cheng G, Zhang F, Zhang L. Delineating antibody recognition against Zika virus during natural infection. JCI Insight. 2017 Jun 15;2(12). pii: 93042.

Zhang Q*, Gui M*, Niu X*, He S, Wang R, Feng Y, Kroeker A, Zuo Y, Wang H, Wang Y, Li J, Li C, Shi Y, Shi X, Gao GF, Xiang Y, Qiu X,Chen L, Zhang L. Potent neutralizing monoclonal antibodies against Ebola virus infection. Sci Rep. 2016 May 16;6:25856. DOI: 10.1038/srep25856.

Email: zhangqi2013 at mail.tsinghua.edu.cn

Phone: +86-10-62797532